UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials

JAMA neurology, 2020-09, Vol.77 (9), p.1132

2020

Volltextzugriff (PDF)

Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study

Multiple sclerosis, 2018-06, Vol.24 (7), p.963-973

2018

Volltextzugriff (PDF)

Estimating drug concentration–response relationships by applying causal inference methods for continuous point exposures and time-to-event outcomes

Statistical methods in medical research, 2023-12, Vol.32 (12), p.2440-2454

2023

Volltextzugriff (PDF)

Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS

Multiple sclerosis, 2022-10, Vol.28 (12), p.1927-1936

2022

Volltextzugriff (PDF)

Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies

Lancet neurology, 2017-11, Vol.16 (11), p.925-933

2017

Volltextzugriff (PDF)

COVID-19 in persons with multiple sclerosis treated with ocrelizumab – A pharmacovigilance case series

Multiple sclerosis and related disorders, 2020-07, Vol.42, p.102192, Article 102192

2020

Volltextzugriff (PDF)

Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis

Neurology, 2021-10, Vol.97 (16), p.e1546

2021

Volltextzugriff (PDF)

Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial

Lancet neurology, 2020-12, Vol.19 (12), p.998-1009

2020

Volltextzugriff (PDF)

Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension

Neurology, 2020-09, Vol.95 (13), p.e1854

2020

Volltextzugriff (PDF)

Evaluation of NEDA as a Predictor of Disease Progression in Patients With RMS and PPMS Treated With Ocrelizumab: Post-Hoc Analyses From the OPERA I/OPERA II and ORATORIO Trials (P16-4.007)

Neurology, 2022-05, Vol.98 (18_supplement)

2022

Volltextzugriff (PDF)

COVID-19 in ocrelizumab-treated people with multiple sclerosis

Multiple sclerosis and related disorders, 2021-04, Vol.49, p.102725-102725, Article 102725

2021

Volltextzugriff (PDF)

COVID-19 in persons with multiple sclerosis treated with ocrelizumab - A pharmacovigilance case series

Multiple sclerosis and related disorders, 2020-07, Vol.42, p.102192-102192

2020

Volltextzugriff (PDF)

031 Long-term efficacy of ocrelizumab in primary progressive multiple sclerosis: 6.5-study years

Journal of neurology, neurosurgery and psychiatry, 2022-06, Vol.93 (6), p.A23-A23

2022

Volltextzugriff (PDF)

020 Long-term efficacy of ocrelizumab in relapsing multiple sclerosis: 6 study years

Journal of neurology, neurosurgery and psychiatry, 2022-06, Vol.93 (6), p.A19-A20

2022

Volltextzugriff (PDF)

034 Updated safety analysis of ocrelizumab in multiple sclerosis

Journal of neurology, neurosurgery and psychiatry, 2022-06, Vol.93 (6), p.A24-A24

2022

Volltextzugriff (PDF)

Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis

Neurology, 2019-11, Vol.93 (19), p.e1778

2019

Volltextzugriff (PDF)

Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials

European journal of neurology, 2022-04, Vol.29 (4), p.1238-1242

2022

Volltextzugriff (PDF)

Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients With Relapsing and Primary Progressive Multiple Sclerosis (1147)

Neurology, 2020-04, Vol.94 (15_supplement)

2020

Volltextzugriff (PDF)

B-Cell Subset Depletion Following Ocrelizumab Treatment in Patients With Relapsing Multiple Sclerosis (4292)

Neurology, 2021-04, Vol.96 (15_supplement)

2021

Volltextzugriff (PDF)

177 Updated safety analysis of ocrelizumab in multiple sclerosis

Journal of neurology, neurosurgery and psychiatry, 2019-12, Vol.90 (12), p.e47.1-e47

2019

Volltextzugriff (PDF)

Routine Laboratory Measures in the Controlled-Treatment Period of Phase III Ocrelizumab Trials in Relapsing and Progressive Multiple Sclerosis (P5.425)

Neurology, 2018-04, Vol.90 (15_supplement)

2018

Volltextzugriff (PDF)

Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients With Relapsing and Primary Progressive Multiple Sclerosis (P4.2-025)

Neurology, 2019-04, Vol.92 (15_supplement)

2019

Volltextzugriff (PDF)

Ocrelizumab exposure in relapsing–remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension

Journal of neurology, 2024-02, Vol.271 (2), p.642-657

2024

Volltextzugriff (PDF)

Sustained Reduction in Confirmed Disability Progression in Patients with Primary Progressive MS Treated with Ocrelizumab: 6.5-study Year Follow-up Data (1807)

Neurology, 2020-04, Vol.94 (15_supplement)

2020

Volltextzugriff (PDF)

Long-term Reduction of Confirmed Disability Progression and Time to Walking Aid After 6 Years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis (1847)

Neurology, 2020-04, Vol.94 (15_supplement)

2020

Volltextzugriff (PDF)

1 – 25 von 48

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(22)

Publikationsform

Artikel
(48)

Sprache

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials

Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study

Estimating drug concentration–response relationships by applying causal inference methods for continuous point exposures and time-to-event outcomes

Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS

Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies

COVID-19 in persons with multiple sclerosis treated with ocrelizumab – A pharmacovigilance case series

Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis

Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial

Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension

Evaluation of NEDA as a Predictor of Disease Progression in Patients With RMS and PPMS Treated With Ocrelizumab: Post-Hoc Analyses From the OPERA I/OPERA II and ORATORIO Trials (P16-4.007)

COVID-19 in ocrelizumab-treated people with multiple sclerosis

COVID-19 in persons with multiple sclerosis treated with ocrelizumab - A pharmacovigilance case series

031 Long-term efficacy of ocrelizumab in primary progressive multiple sclerosis: 6.5-study years

020 Long-term efficacy of ocrelizumab in relapsing multiple sclerosis: 6 study years

034 Updated safety analysis of ocrelizumab in multiple sclerosis

Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis

Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials

Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients With Relapsing and Primary Progressive Multiple Sclerosis (1147)

B-Cell Subset Depletion Following Ocrelizumab Treatment in Patients With Relapsing Multiple Sclerosis (4292)

177 Updated safety analysis of ocrelizumab in multiple sclerosis

Routine Laboratory Measures in the Controlled-Treatment Period of Phase III Ocrelizumab Trials in Relapsing and Progressive Multiple Sclerosis (P5.425)

Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients With Relapsing and Primary Progressive Multiple Sclerosis (P4.2-025)

Ocrelizumab exposure in relapsing–remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension

Sustained Reduction in Confirmed Disability Progression in Patients with Primary Progressive MS Treated with Ocrelizumab: 6.5-study Year Follow-up Data (1807)

Long-term Reduction of Confirmed Disability Progression and Time to Walking Aid After 6 Years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis (1847)

Suchergebnisse filtern